Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:

‍

In a study published in Nature, a research team led by scientist Melanie Balbach of Weill Cornell Medicine, detailed a potential new male birth control. Testing an eye disease drug on mice, Balbach recognized it applied to the molecular pathway for male fertility. (Washington Post)

CNBC looks at the methods pharmaceutical companies like Eli Lilly are using to increase diversity in clinical trials, including sending mobile research units to community events.

Genetic Engineering & Biotechnology News discusses two upcoming clinical studies conducted by Psycheceutical Bioscience, and Australia-based CRO, iNGENū, researching the efficacy of a topical ketamine therapeutic for the treatment of PTSD.

‍

‍
‍

Our Culture

"We create a template so we can pull back the timelines and eliminate concerns around quality and risk—because everything’s already validated in the design. Then we can work faster with no risk to quality."

   –Jamie, Trial Delivery

‍‍
‍

About Judi

Judi speeds and improves the world's clinical trial workflows. Our cloud-based platform has 120,000 users across 171 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 certified collaboration platform.

‍

‍

‍

‍